About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 501796, 15 pages
http://dx.doi.org/10.1155/2012/501796
Research Article

Fermented Mistletoe Extract as a Multimodal Antitumoral Agent in Gliomas

1Laboratory for Molecular Neuro-Oncology, Hertie Institute for Clinical Brain Research and Center Neurology, University of Tübingen, Otfried-Müller-Straße 27, 72076 Tübingen, Germany
2Institute of Neurology (Edinger-Institute), Goethe University of Frankfurt, Heinrich-Hoffmann-Straße 7, 60528 Frankfurt, Germany
3Neuroimmunology, Department of General Neurology, Hertie Institute for Clinical Brain Research and Center Neurology, University of Tübingen, Otfried-Müller-Straße 27, 72076 Tübingen, Germany

Received 26 July 2012; Accepted 5 September 2012

Academic Editor: Arndt Büssing

Copyright © 2012 Oliver Podlech et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Hermisson, A. Klumpp, W. Wick et al., “O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells,” Journal of Neurochemistry, vol. 96, no. 3, pp. 766–776, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Weller, J. Rieger, C. Grimmel et al., “Predicting chemoresistance in human malignant glioma cells: the role of molecular genetic analyses,” International Journal of Cancer, vol. 79, no. 6, pp. 640–644, 1998.
  4. M. Weller and A. Fontana, “The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain,” Brain Research Reviews, vol. 21, no. 2, pp. 128–151, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Platten, W. Wick, and M. Weller M, “Malignant glioma biology: role for TGF-beta in growth, motility, angiogenesis, and immune escape,” Microscopic Research Technology, vol. 52, no. 4, pp. 401–410, 2001.
  6. G. Nikolai, P. Friedl, M. Werner, B. Niggemann, and K. S. Zänker, “Effect of a mistletoe extract (Iscador® QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices,” In Vitro Cellular and Developmental Biology, vol. 33, no. 9, pp. 710–716, 1997. View at Scopus
  7. A. Gren, “Effects of Iscador preparations on the reactivity of mouse immune system,” Neuroendocrinology Letters, vol. 30, no. 4, pp. 530–534, 2009. View at Scopus
  8. C. H. Lee, J. K. Kim, H. Y. Kim, S. M. Park, and S. M. Lee, “Immunomodulating effects of Korean mistletoe lectin in vitro and in vivo,” International Immunopharmacology, vol. 9, no. 13-14, pp. 1555–1561, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Braedel-Ruoff, “Immunomodulatory effects of Viscum album extracts on natural killer cells: review of clinical trials,” Forschende Komplementarmedizin, vol. 17, no. 2, pp. 63–73, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. G. M. Stein, A. Büssing, and M. Schietzel, “Stimulation of the maturation of dendritic cells in vitro by a fermented mistletoe extract,” Anticancer Research, vol. 22, no. 6, pp. 4215–4219, 2002. View at Scopus
  11. T. Hajtó, K. Fodor, P. Perjési, and P. Németh, “Difficulties and perspectives of immunomodulatory therapy with mistletoe lectins and standardized mistletoe extracts in evidence-based medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2011, Article ID 298972, 6 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. N. E. Gardin, “Immunological response to mistletoe (Viscum album L.) in cancer patients: a four-case series,” Phytotherapy Research, vol. 23, no. 3, pp. 407–411, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. J. Park, J. H. Hong, H. J. Kwon et al., “TLR4-mediated activation of mouse macrophages by Korean mistletoe lectin-C (KML-C),” Biochemical and Biophysical Research Communications, vol. 396, no. 3, pp. 721–725, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. F. Stirpe, K. Sandvig, S. Olsnes, and A. Pihl, “Action of viscumin, a toxic lectin from mistletoe, on cells in culture,” Journal of Biological Chemistry, vol. 257, no. 22, pp. 13271–13277, 1982. View at Scopus
  15. A. Büssing and M. Schietzel, “Apoptosis-inducing properties of Viscum album L. extracts from different host trees, correlate with their content of toxic mistletoe lectins,” Anticancer Research, vol. 19, no. 1, pp. 23–28, 1999. View at Scopus
  16. A. Büssing, K. Suzart, and K. Schweizer, “Differences in the apoptosis-inducing properties of Viscum album L. extracts,” Anti-Cancer Drugs, vol. 8, no. 1, supplement, pp. S9–S14, 1997. View at Scopus
  17. A. M. Burger, U. Mengs, J. B. Schüler, and H. H. Fiebig, “Antiproliferative activity of an aqueous mistletoe extract in human tumor cell lines and xenografts in vitro,” Arzneimittel-Forschung, vol. 51, no. 9, pp. 748–757, 2001. View at Scopus
  18. W. B. Park, S. Y. Lyu, J. H. Kim et al., “Inhibition of tumor growth and metastasis by Korean mistletoe lectin is associated with apoptosis and antiangiogenesis,” Cancer Biotherapy and Radiopharmaceuticals, vol. 16, no. 5, pp. 439–447, 2001. View at Scopus
  19. S. H. Choi, S. Y. Lyu, and W. B. Park, “Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt,” Archives of Pharmacal Research, vol. 27, no. 1, pp. 68–76, 2004. View at Scopus
  20. S. Y. Lyu, W. B. Park, K. H. Choi, and W. H. Kim, “Involvement of caspase-3 in apoptosis induced by Viscum album var. coloratum agglutinin in HL-60 cells,” Bioscience, Biotechnology and Biochemistry, vol. 65, no. 3, pp. 534–541, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Y. Lyu and W. B. Park, “Mistletoe lectin (Viscum album coloratum) modulates proliferation and cytokine expressions in murine splenocytes,” Journal of Biochemistry and Molecular Biology, vol. 39, no. 6, pp. 662–670, 2006. View at Scopus
  22. A. Thies, P. Dautel, A. Meyer, U. Pfüller, and U. Schumacher, “Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model,” British Journal of Cancer, vol. 98, no. 1, pp. 106–112, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Beuth, H. L. Ko, H. Schneider et al., “Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model,” Anticancer Research, vol. 26, no. 6, pp. 4451–4456, 2006. View at Scopus
  24. I. F. Pryme, S. Bardocz, A. Pusztai, and S. W. B. Ewen, “Suppression of growth of tumour cell lines in vitro and tumours in vivo by mistletoe lectins,” Histology and Histopathology, vol. 21, no. 1–3, pp. 285–299, 2006. View at Scopus
  25. A. M. Burger, U. Mengs, J. B. Schüler, and H. H. Fiebig, “Anticancer activity of an aqueous mistletoe extract (AME) in syngeneic murine tumor models,” Anticancer Research, vol. 21, no. 3, pp. 1965–1968, 2001. View at Scopus
  26. D. Lenartz, J. Andermahr, G. Plum, J. Menzel, and J. Beuth, “Efficiency of treatment with galactoside-specific lectin from mistletoe against rat glioma,” Anticancer Research, vol. 18, no. 2, pp. 1011–1014, 1998. View at Scopus
  27. A. Büssing, C. Raak, and T. Ostermann, “Quality of life and related dimensions in cancer patients treated with mistletoe extract (Iscador): a meta-analysis,” Evidence Based Complementary and Alternative Medicine, vol. 2012, Article ID 219402, 8 pages, 2012. View at Publisher · View at Google Scholar
  28. H. Matthes, W. E. Friedel, P. R. Bock, and K. S. Zänker, “Molecular mistletoe therapy: friend or foe in established antitumor protocols? a multicenter, controlled, retrospective pharmaco-epidemiological study in pancreas cancer,” Current Molecular Medicine, vol. 10, no. 4, pp. 430–439, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. G. S. Kienle and H. Kiene, “Influence of Viscum album L (European Mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies,” Integrative Cancer Therapies, vol. 9, no. 2, pp. 142–157, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. T. Ostermann, C. Raak, and A. Büssing, “Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review,” BMC Cancer, vol. 9, article 451, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Ziegler and R. Grossarth-Maticek, “Individual patient data meta-analysis of survival and psychosomatic self-regulation from published prospective controlled cohort studies for long-term therapy of breast cancer patients with a mistletoe preparation (Iscador),” Evidence-Based Complementary and Alternative Medicine, vol. 7, no. 2, pp. 157–166, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. D. Lenartz, U. Dott, J. Menzel, J. M. Schierholz, and J. Beuth, “Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe,” Anticancer Research, vol. 20, no. 3, pp. 2073–2076, 2000. View at Scopus
  33. M. A. Friese, M. Platten, S. Z. Lutz et al., “MICA/NKG2D-mediated immunogene therapy of experimental gliomas,” Cancer Research, vol. 63, no. 24, pp. 8996–9006, 2003. View at Scopus
  34. S. Antony, R. Kuttan, and G. Kuttan, “Role of natural killer cells in Iscador mediated inhibition of metastasis by adoptive immunotherapy,” Immunological Investigations, vol. 29, no. 3, pp. 219–231, 2000. View at Scopus
  35. N. Ishii, D. Maier, A. Merlo et al., “Frequent co-alterations of TP53, p16/CDKN2A, p14(ARF), PTEN tumor suppressor genes in human glioma cell lines,” Brain Pathology, vol. 9, no. 3, pp. 469–479, 1999. View at Scopus
  36. T. E. Vanmeter, H. K. Rooprai, M. M. Kibble, H. L. Fillmore, W. C. Broaddus, and G. J. Pilkington, “The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis,” Journal of Neuro-Oncology, vol. 53, no. 2, pp. 213–235, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Wick, M. Platten, and M. Weller, “Glioma cell invasion: regulation of metalloproteinase activity by TGF-β,” Journal of Neuro-Oncology, vol. 53, no. 2, pp. 177–185, 2001. View at Publisher · View at Google Scholar · View at Scopus
  38. G. J. Pilkington, J. L. Darling, P. L. Lantos, and D. G. T. Thomas, “Cell lines (VMDk) derived from a spontaneous murine astrocytoma. Morphological and immunocytochemical characterization,” Journal of the Neurological Sciences, vol. 62, no. 1–3, pp. 115–139, 1983. View at Scopus
  39. G. J. Pilkington, J. L. Darling, P. L. Lantos, and D. G. T. Thomas, “Tumorigenicity of cell lines (VMDk) derived from a spontaneous murine astrocytoma. Histology, fine structure and immunocytochemistry of tumours,” Journal of the Neurological Sciences, vol. 71, no. 2-3, pp. 145–164, 1985. View at Scopus
  40. U. Naumann, S. Kügler, H. Wolburg et al., “Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand,” Cancer Research, vol. 61, no. 15, pp. 5833–5842, 2001. View at Scopus
  41. J. Seznec, B. Silkenstedt, and U. Naumann, “Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma,” Jorunal of Neurooncology, vol. 101, pp. 365–377, 2011.
  42. S. A. Steinle, P. Li, D. L. Morris et al., “Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family,” Immunogenetics, vol. 53, no. 4, pp. 279–287, 2001.
  43. E. Adamopoulou, J. Diekmann, E. Tolosa et al., “Human CD4+ T cells displaying viral epitopes elicit a functional virus-specific memory CD8+ T cell response,” Journal of Immunology, vol. 178, no. 9, pp. 5465–5472, 2007. View at Scopus
  44. V. Koka, A. Potti, S. E. Forseen et al., “Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme,” American Journal of Clinical Oncology, vol. 26, no. 4, pp. 332–335, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Sasaki, M. B. S. Lopes, G. R. Hankins, and G. A. Helm, “Expression of survivin, an inhibitor of apoptosis protein, in tumors of the nervous system,” Acta Neuropathologica, vol. 104, no. 1, pp. 105–109, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. M. M. Georgescu, “Pten tumor suppressor network in PI3K-Akt pathway control,” Genes and Cancer, vol. 1, no. 12, pp. 1170–1177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. D. Koul, “PTEN signaling pathways in glioblastoma,” Cancer Biology and Therapy, vol. 7, no. 9, pp. 1321–1325, 2008. View at Scopus
  48. L. Klampfer, “Signal transducers and activators of transcription (STATs): novel targets of chemopreventive and chemotherapeutic drugs,” Current Cancer Drug Targets, vol. 6, no. 2, pp. 107–121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Liu, C. Sun, H. Huang, K. Janda, and T. Edgington, “Overexpression of legumain in tumors is significant for invasion/metastasis and a candidate enzymatic target for prodrug therapy,” Cancer Research, vol. 63, no. 11, pp. 2957–2964, 2003. View at Scopus
  50. M. M. Bernardo and R. Fridman, “TIMP-2 (tissue inhibitor of metalloproteinase-2) regulates MMP-2 (matrix metalloproteinase-2) activity in the extracellular environment after pro-MMP-2 activation by MT1 (membrane type 1)-MMP,” Biochemical Journal, vol. 374, no. 3, pp. 739–745, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. K. V. Lu, K. A. Jong, A. K. Rajasekaran, T. F. Cloughesy, and P. S. Mischel, “Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line,” Laboratory Investigation, vol. 84, no. 1, pp. 8–20, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. E. I. Deryugina, M. A. Bourdon, G. X. Luo, R. A. Reisfeld, and A. Strongin, “Matrix metalloproteinase-2 activation modulates glioma cell migration,” Journal of Cell Science, vol. 110, no. 19, pp. 2473–2482, 1997. View at Scopus
  53. P. Quo, Y. Imanishi, F. C. Cackowski et al., “Up-regulation of angiopoietin-2, matrix metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 γ 2 correlates with the invasiveness of human glioma,” American Journal of Pathology, vol. 166, no. 3, pp. 877–890, 2005. View at Scopus
  54. C. Munaut, A. Noël, O. Hougrand, J. M. Foidart, J. Boniver, and M. Deprez, “Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas,” International Journal of Cancer, vol. 106, no. 6, pp. 848–855, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. O. H. Lee, J. Xu, J. Fueyo et al., “Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin β1-dependent adhesion to the extracellular matrix,” Molecular Cancer Research, vol. 4, no. 12, pp. 915–926, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. G. Kuttan and R. Kuttan, “Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation,” Cancer Letters, vol. 66, no. 2, pp. 123–130, 1992. View at Publisher · View at Google Scholar · View at Scopus
  57. M. Schink, W. Tröger, A. Dabidian et al., “Mistletoe extract reduces the surgical suppression of natural killer cell activity in cancer patients. A randomized phase III trial,” Forschende Komplementarmedizin, vol. 14, no. 1, pp. 9–17, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. M. O. Li, Y. Y. Wan, S. Sanjabi, A. K. L. Robertson, and R. A. Flavell, “Transforming growth factor-β regulation of immune responses,” Annual Review of Immunology, vol. 24, pp. 99–146, 2006. View at Publisher · View at Google Scholar · View at Scopus